ATE331728T1 - Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie - Google Patents

Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie

Info

Publication number
ATE331728T1
ATE331728T1 AT95934432T AT95934432T ATE331728T1 AT E331728 T1 ATE331728 T1 AT E331728T1 AT 95934432 T AT95934432 T AT 95934432T AT 95934432 T AT95934432 T AT 95934432T AT E331728 T1 ATE331728 T1 AT E331728T1
Authority
AT
Austria
Prior art keywords
phospor
radioactive
protein labeling
targeted radiotherapy
radiotherapy
Prior art date
Application number
AT95934432T
Other languages
English (en)
Inventor
Gary L Griffiths
Hans J Hansen
Habibe Karacay
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE331728T1 publication Critical patent/ATE331728T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95934432T 1994-10-05 1995-09-21 Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie ATE331728T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/318,917 US5728369A (en) 1994-10-05 1994-10-05 Radioactive phosphorus labeling of proteins for targeted radiotherapy

Publications (1)

Publication Number Publication Date
ATE331728T1 true ATE331728T1 (de) 2006-07-15

Family

ID=23240116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95934432T ATE331728T1 (de) 1994-10-05 1995-09-21 Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie

Country Status (9)

Country Link
US (2) US5728369A (de)
EP (1) EP0787138B1 (de)
JP (1) JPH10509425A (de)
AT (1) ATE331728T1 (de)
AU (1) AU3677095A (de)
CA (1) CA2200855C (de)
DE (1) DE69535094T2 (de)
IL (1) IL115416A (de)
WO (1) WO1996011208A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7312318B2 (en) * 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
EP1460166B1 (de) * 2001-12-27 2015-10-21 Fiber Glass Japan Kabushiki Kaisha Bindemittel für glasfaser, glasfaser als verstärkungsmittel für olefinharz sowie verfahren zur herstellung einer olefinharz zusammensetzung für faserverstärkte formkörper
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7371852B2 (en) * 2003-01-22 2008-05-13 Serenex, Inc. Alkyl-linked nucleotide compositions
US6893626B2 (en) * 2003-02-18 2005-05-17 Edward T. Wei Compositions for TRP-M8 binding and radioreceptor methods therewith
US7169377B2 (en) 2003-10-15 2007-01-30 Wei Edward T Radioligands for the TRP-M8 receptor and methods therewith
US6887952B1 (en) * 2004-02-12 2005-05-03 Biosite, Inc. N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2994491A4 (de) 2013-05-10 2016-12-07 Whitehead Inst Biomedical Res In-vitro-herstellung von erythrozyten mit sortasefähigen proteinen
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
US10053683B2 (en) 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
US20180104251A1 (en) 2015-03-09 2018-04-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for the treatment of glioblastoma
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
SG11201807459VA (en) 2016-10-24 2018-09-27 Crrc Yangtze Co Ltd Straddle-type multimodal transport interconnecting system
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186579B (en) * 1986-01-21 1990-07-25 Brian Maurice John Foxwell Improvements relating to the radio-labelling of proteins
GB8906708D0 (en) * 1989-03-23 1989-05-10 Foxwell Brian M J Improvements relating to the radiolabelling of proteins
GB9126650D0 (en) * 1991-12-16 1992-02-12 Creighton Andrew M Further improvements relating to the radiolabelling of proteins

Also Published As

Publication number Publication date
WO1996011208A1 (en) 1996-04-18
JPH10509425A (ja) 1998-09-14
IL115416A0 (en) 1995-12-31
DE69535094D1 (de) 2006-08-10
EP0787138B1 (de) 2006-06-28
EP0787138A1 (de) 1997-08-06
US5728369A (en) 1998-03-17
AU3677095A (en) 1996-05-02
DE69535094T2 (de) 2007-02-01
US5976492A (en) 1999-11-02
IL115416A (en) 2000-07-26
EP0787138A4 (de) 2000-03-08
CA2200855C (en) 2001-04-10
CA2200855A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
ATE331728T1 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ATE365808T1 (de) Transportproteine und deren verwendungen
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
EP0724456A4 (de) Antikörper gegen cd40
NO961161L (no) Metallkomplekser med ladede linkere
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
DE69434384D1 (de) Metalkomplexbildner
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
NO971059D0 (no) Modifiserte human-C3-proteiner
AU8040898A (en) Type-1 ribosome-inactivating protein
MY125980A (en) Highly purified cytokine activating factor and methods of use
DE69028094D1 (de) Konjugate von antikörpern mit variablen domänen
EA200001127A1 (ru) Бактериальные феромоны и их использование
EA200100311A1 (ru) Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств
AR005811A1 (es) Proteina de via complementaria natural modificada, secuencia y construccion de adn que la codifica, conjugado y formulacion farmaceutica que la comprende,su uso y metodo para reducirla en un mamifero.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties